Live tape
Top 8, mentions 7d997GOOGL178 mentions▲ +0.05NVDA167 mentions▲ +0.10SPY149 mentions▲ +0.05QQQ120 mentions▲ +0.08META117 mentions▲ +0.05TSLA91 mentions▲ +0.06AMZN90 mentions▲ +0.04MSFT85 mentions▲ +0.07

Equity · Healthcare

SOLV

Solventum Corporation · NYSE

$87.56 −1.62% 1D Finazon · prior-day close · Sep 17, 2026
Price · Chart
Our own end-of-day closes 47 sessions
$100 $70 23 Jun 17 Sep

The line runs $74.00 on 23 June through $87.56 on 17 September, on a scale from $70 to $100. Days the market did not trade hold the previous close, flat.

The chart above plots the price of SOLV over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 47 sessions over that window: $74.00 on 23 June 2026 through $87.56 on 17 September 2026.

Market cap $14.9B
P/E (TTM) 10.5
52-week range $62 – $92
Avg volume 70.6K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 21, 2026

SOLV insider trades

SEC Form 4 · last 90 days · newest Form 4 filing 1 Sep 2026
Open-market buys 0
Open-market sells 0
Non-trade filings 2

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
01 Sep 2026 Hanson Bryan C Chief Executive Officer Option exercise 67,261
01 Sep 2026 Hanson Bryan C Chief Executive Officer Tax withheld 26,468 $2.41M

SOLV reported financials

SEC EDGAR XBRL

SOLV reported revenue of $8.3B for the fiscal year ended 31 Dec 2025. Net income over the same period was $1.6B.

Figure Reported Period
Revenue $8.3B 31 Dec 2025 fiscal year
Net income $1.6B 31 Dec 2025 fiscal year
Diluted EPS $8.88 31 Dec 2025 fiscal year
Total assets $14.2B 30 Jun 2026 at period end
Total equity $4.8B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

SOLV earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $0.53 $2.21B
31 Mar 2026 Q1 2026 $0.07 $2.01B
31 Dec 2025 FY 2025 $8.88 $8.33B
30 Sep 2025 Q3 2025 $7.22 $2.10B
30 Jun 2025 Q2 2025 $0.51 $2.16B
31 Mar 2025 Q1 2025 $0.78 $2.07B
31 Dec 2024 FY 2024 $2.76 $8.25B
30 Sep 2024 Q3 2024 $0.70 $2.08B

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

SOLV institutional holders

SEC Form 13F

13 of the 45 institutional funds we track reported a SOLV position for the quarter ended 30 Jun 2026 — a combined $938.8M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Trian Fund Management Held (±25%) 8,236,753 $635.5M
Millennium Management Added +122.1% shares 1,199,940 $92.6M
AQR Capital Management Added +48.2% shares 1,082,100 $83.5M
D. E. Shaw & Co. Added +260.9% shares 526,392 $40.6M
Marshall Wace New position 351,518 $27.1M
Balyasny Asset Management New position 247,812 $19.1M
Bridgewater Associates Added +5,167.1% shares 177,921 $13.7M
Tudor Investment Corp New position 118,050 $9.1M
Point72 Asset Management New position 102,705 $7.9M
Citadel Advisors Trimmed −83.6% shares 98,232 $7.6M

Showing the 10 largest of 13 reported positions. The figures above count all of them.

Source: SEC EDGAR 13F filings

SOLV fails-to-deliver

SEC CNS data

On 31 Aug 2026, 3,733 shares of SOLV failed to deliver (about $340K).

Settlement date Shares failed Notional % of shares out
31 Aug 2026 3,733 $340K 0.002%
19 Aug 2026 3,285 $287K 0.002%
13 Aug 2026 155 $13K <0.001%
11 Aug 2026 79 $7K <0.001%

Source: SEC fails-to-deliver (CNS) data

Congressional trades in SOLV

STOCK Act disclosures

The most recent congressional trade disclosed in SOLV is a sale by J. French Hill (house, AR), dated 31 Dec 2025.

Date Member Type Amount
31 Dec 2025 filed 23 Jan 2026 J. French Hill house · Republican–AR Sale $15K–$50K

Source: U.S. House of Representatives financial disclosures